US OKs first-line use of Novartis’ Zykadia in lung cancer
US regulators have green-lighted the use of Novartis Zykadia as a first-line treatment option for some patients with non-small cell lung cancer.
Read More
Tag: ALK positive
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
